首页> 外文期刊>细胞研究(英文版) >Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis
【24h】

Macrophagic CD146 promotes foam cell formation and retention during atherosclerosis

机译:巨噬细胞CD146促进动脉粥样硬化期间泡沫细胞的形成和保留

获取原文
获取原文并翻译 | 示例
       

摘要

The persistence of cholesterol-engorged macrophages (foam cells) in the artery wall fuels the development of atherosclerosis.However,the mechanism that regulates the formation of macrophage foam cells and impedes their emigration out of inflamed plaques is still elusive.Here,we report that adhesion receptor CD146 controls the formation of macrophage foam cells and their retention within the plaque during atherosclerosis exacerbation.CD146 is expressed on the macrophages in human and mouse atheroma and can be upregulated by oxidized low-density lipoprotein (oxLDL).CD146 triggers macrophage activation by driving the internalization of scavenger receptor CD36 during lipid uptake.In response to oxLDL,macrophages show reduced migratory capacity toward chemokines CCL19 and CCL21;this capacity can be restored by blocking CD146.Genetic deletion of macrophagic CD146 or targeting of CD146 with an antibody result in much less complex plaques in high-fat diet-fed ApoE-/-mice by causing lipid-loaded macrophages to leave plaques.Collectively,our findings identify CD146 as a novel retention signal that traps macrophages within the artery wall,and a promising therapeutic target in atherosclerosis treatment.
机译:动脉壁中胆固醇增高的巨噬细胞(泡沫细胞)的持续存在助长了动脉粥样硬化的发展。然而,调节巨噬细胞泡沫细胞形成并阻止其从发炎斑块中迁移的机制仍然难以捉摸。在此,我们报道粘附受体CD146控制着巨噬细胞泡沫细胞的形成及其在动脉粥样硬化加重过程中在斑块内的保留.CD146在人和小鼠动脉粥样硬化的巨噬细胞上表达,并可以被氧化的低密度脂蛋白(oxLDL)上调.CD146触发巨噬细胞的活化在脂质摄取过程中驱动清道夫受体CD36的内在化。响应oxLDL,巨噬细胞对趋化因子CCL19和CCL21的迁移能力降低;可以通过阻断CD146来恢复这种能力。巨噬CD146的基因缺失或以抗体靶向CD146导致高脂饮食喂养的ApoE //小鼠中的脂质斑块引起的复杂斑块少得多总的来说,我们的发现将CD146识别为一种新的保留信号,将巨噬细胞捕获在动脉壁内,并有望成为动脉粥样硬化治疗的治疗靶点。

著录项

  • 来源
    《细胞研究(英文版)》 |2017年第3期|352-372|共21页
  • 作者单位

    Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,China;

    Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,China;

    Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,China;

    Beijing Anzhen Hospital of the Capital University of Medical Sciences, Beijing 100029, China;

    Beijing Anzhen Hospital of the Capital University of Medical Sciences, Beijing 100029, China;

    Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,China;

    Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,China;

    Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,China;

    Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,China;

    Key Laboratory of Protein and Peptide Pharmaceutical, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,China;

  • 收录信息 中国科学引文数据库(CSCD);中国科技论文与引文数据库(CSTPCD);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 04:01:42
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号